[MTOR inhibitors: from transplantation to oncology. AFU 2006 Transplantation Committee Review of the literature]

Abstract : The use of mTOR inhibitors started about 30 years ago following the discovery of rapamycin, a macrolide derived from a soilborne microorganism Streptomyces hygroscopicus that exerts antibiotic, immunosuppressive and antiproliferative properties. Initially intended to be used as an antibiotic, a more detailed understanding of the mechanism of action of this class of drugs has rationalized and validated its use in the field of transplantation and oncology. Many clinical trials on mTOR inhibitors have been conducted in these two fields, in which urologists are actively involved. This review summarizes the current knowledge on the mechanism of action and clinical applications of mTOR inhibitors in renal transplantation and oncology.
Type de document :
Article dans une revue
Progrès en Urologie, Elsevier Masson, 2007, 17 (5), pp.928-33
Liste complète des métadonnées

http://www.hal.inserm.fr/inserm-00479738
Contributeur : Philippe Saas <>
Soumis le : dimanche 2 mai 2010 - 14:25:28
Dernière modification le : lundi 27 août 2018 - 09:44:38

Identifiants

  • HAL Id : inserm-00479738, version 1
  • PUBMED : 17969790

Collections

Citation

Yann Neuzillet, Georges Karam, Eric Lechevallier, François Kleinclauss. [MTOR inhibitors: from transplantation to oncology. AFU 2006 Transplantation Committee Review of the literature]. Progrès en Urologie, Elsevier Masson, 2007, 17 (5), pp.928-33. 〈inserm-00479738〉

Partager

Métriques

Consultations de la notice

86